Product
AI AGENTS
INTELLIGENCE SUITE
API, MCP & INTEGRATION
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
Patsnap Eureka Platform
IP Search Agents
IP Drafting Agents
Engineering Agents
Find Solutions with TRIZ
Life Sciences Agents
Materials Agents
SEP Agents
Patsnap Eureka Desktop
BetaAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisProfessional Services
Open Platform
Developer Center
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Free tools
NEWWebinars & Training
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Already have an account? Log In
To start using Patsnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report How does robot-assisted minimally invasive surgery differ from conventional laparoscopy? Explore the key engineering design constraints shaping next-gen surgical systems.
Article | Report How engineers design explosion-proof enclosures for electronic systems in hazardous environments: ATEX, IECEx, flameproof methods, and certification strategies.
Article | Report Iberdomide's EXCALIBER-RRMM Phase III trial positions CELMoD agents as the next-generation successor to lenalidomide in relapsed/refractory multiple myeloma.
Article | Report How AI-assisted code generation is reshaping firmware development workflows for embedded systems engineers — productivity, IP, and best practices.
Article | Report MET/VEGFR inhibitor zanzalintinib combined with atezolizumab targets metastatic colorectal cancer via dual pathway blockade. Explore the molecular rationale and IP landscape.
Article | Report Lanifibranor's NATiV3 Phase III readout is the most anticipated MASH event of 2026. Explore the pan-PPAR mechanism, histological endpoints, and competitive pipeline.
Article | Report How digital thread implementation transforms configuration management in aerospace MRO — covering model-based definition, part traceability, PLM integration, and regulatory compliance.
Article | Report How does amivantamab subcutaneous monthly dosing plus lazertinib stack up against osimertinib in first-line EGFR-mutant NSCLC? Clinical data, IP signals, and competitive analysis.
Article | Report How do engineers balance power density and thermal reliability in next-gen server PSU design? Explore key topologies, GaN/SiC devices, cooling strategies, and IP trends.
Article | Report Vertex Pharmaceuticals' suzetrigine targets NaV1.8 sodium channels for diabetic peripheral neuropathy. Explore the Phase III DPN program, patent landscape, and clinical implications.
Article | Report How AR-assisted assembly guidance reduces error rates in complex electronics manufacturing — technical mechanisms, innovation trends, and IP landscape analysis.
Article | Report ITM-11 (177Lu-edotreotide) NDA targets GEP-NET PRRT approval. Explore how it competes with Lutathera, key patent signals, and the second PRRT race.
Article | Report How engineers tackle electromagnetic interference shielding in wearable medical device design — materials, circuit techniques, regulatory standards, and patent strategies.
Article | Report How conformal cooling channel designs in injection mold tooling reduce warpage in complex polymer parts — engineering principles, thermal management, and IP landscape.
Article | Report Petosemtamab (MCLA-158) targets EGFR and LGR5 in HNSCC. Explore the Merus bispecific pipeline, Phase III design, and competitive landscape in head and neck cancer.